5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Leukemia

Interventions

DRUG

5-Azacytidine

75 mg/m\^2 IV daily x 5 days on days 1 to 5.

DRUG

Lenalidomide

Starting dose 10 mg orally daily x 5 days on days 6 to 10.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston